

## Anti-C5 [Eculizumab] Standard Size Ab00296-10.0

**Isotype and Format:** Human IgG1, Kappa

**Clone Number:** Eculizumab

**Alternative Name(s) of Target:** Complement Component 5; CPAMD4; Complement protein C5; h5G1.1

**UniProt Accession Number of Target Protein:** P01031

**Published Application(s):** Block, ELISA, EM

**Published Species Reactivity:** Human

**Immunogen:** C5 is activated by C5 convertase into C5a, an anaphylatoxin, and C5b a component of the membrane attack complex.

**Specificity:** Binds human C5 centred in the MG7 domain, at an epitope spanning Lys-879 to Arg-885 (Jore et al. 2016) Polymorphisms at Arg-885 correlate with drug resistance. Eculizumab demonstrates no appreciable species cross-reactivity. It is highly species specific. with no appreciable activity against chimpanzee, baboon, rhesus or cynomolgous monkey, pig, rabbit, guinea pig, or rat complement

**Application Notes:** This antibody inhibits activation of C5. The human Fab version (Ab00296-10.6) of this antibody was used by Jore et al. (2016, PMID: 27018802) to determine the binding site of this antibody to C5.

**Antibody First Published in:** Rother et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. [PMID:17989688](#)

**Note on publication:** Describes development and characterisation of Eculizumab.

## Product Form

**Size:** 100 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.